Equity Offerings

Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced that it is offering to sell 6,800,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Barclays Capital Inc. is the sole book-running manager of the offering, and Halozyme intends to grant them a thirty (30) day option to purchase up to an additional 1,020,000 shares of common stock. All of the shares in the offering are to be sold by Halozyme. Halozyme intends to use the net proceeds from the offering to build commercial inventory for anticipated product launches, fund research and development of proprietary programs, and for general corporate purposes.

EV Energy Partners, L.P. (NASDAQ: EVEP) (the "Partnership") today announced that it has commenced an underwritten public offering of 3,200,000 of its common units representing limited partner interests. The Partnership also intends to grant the underwriters a 30-day option to purchase up to 480,000 additional common units to cover over-allotments, if any.

The Partnership intends to use the net proceeds from the offering, including the proceeds from any exercise of the over-allotment option of common units, to repay indebtedness under its existing revolving credit facility.

Apricus Biosciences, Inc. (Nasdaq: APRI) has priced an underwritten public offering of 4,938,272 units at a price to the public of $4.05 per unit, for gross offering proceeds of $20.0 million. Each unit consists of (i) one share of common stock and (ii) one warrant to purchase 0.50 of a share of common stock. The shares of common stock and warrants are immediately separable and will be issued separately, and no units will be issued or certificated. The warrants are exercisable immediately upon issuance, having a five-year term and an exercise price of $5.25 per share. The warrants will be certificated, and will be delivered to the investors by physical delivery following the closing. There is no established public trading market for the warrants and we do not expect a market to develop. In addition, Apricus Bio has granted the underwriters a 30 day option to purchase up to an additional 740,740 Units to cover over-allotments, if any. The net offering proceeds to Apricus Bio from this offering are expected to be approximately $18.4 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about February 14, 2012, subject to customary closing conditions.

Array BioPharma Inc. (NASDAQ: ARRY) announced today the pricing of an underwritten public offering of 20,000,000 primary shares of its common stock at a public offering price of $2.60 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $52 million.

The offering is expected to close on or about February 14, 2012, subject to customary closing conditions. Array also granted the underwriters a 30-day option to purchase 3,000,000 additional shares of common stock to cover over-allotments, if any. All of the shares sold in the offering are being sold by Array, with the proceeds to be used to fund research and development activities and for general corporate purposes. Jefferies & Company, Inc. and Leerink Swann LLC are acting as joint book-running managers for the offering. Stifel Nicolaus Weisel is acting as co-manager for the offering.

Array Biopharma (Nasdaq: ARRY) prices 20 million shares at $2.60/share